Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

China Risun (1907 HK): Even Greater Profits Or A Steel Trap?

China Risun (中国旭阳) IPO Quick Note: Past the Peak of Coking Cycle

Sinochem Energy (中化能源) IPO: Behind the PX Curve, Valuation Stretched at USD 10 Bn

Sinochem Energy (中化能源) IPO First Impression: Trophy Asset Mixed with Volatile Trading Business

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

China Risun Group  / Equity Capital Markets

<p><a href="https://www.smartkarma.com/entities/27956" target="_blank" data-smartkarma-citation="entities:27956:1">China Risun (1907 HK)</a> raised USD 202 million at HKD 2.80 per share, near the low end of its IPO price range. We have previously covered the IPO in:</p><ul><li><a href="https://www.smartkarma.com/insights/china-risun-ipo-quick-note-past-the-peak-of-coking-cycle" target="_blank" data-smartkarma-citation="insights:28269">China Risun (中国旭阳) IPO Quick Note: Past the Peak of Coking Cycle</a></li></ul><p>In this insight, we will update on the deal dynamics, implied valuation, and include a valuation sensitivity table.</p>

China Risun (1907 HK) raised USD 202 million at HKD 2.80 per share, near the low end of its IPO price range. We have previously covered the IPO in:China Risun (中国旭阳) IPO Quick Note: Past the Peak of Coking CycleIn this insight, we will update on the deal dynamics, implied valuation, and include a valuation sensitivity table.

China Risun (中国旭阳) - Quick Post-IPO Trading Update